HLS Therapeutics Inc
🇨🇦XTSE.HLSCanadaHealthcare
PriceCA$4.00+0.06 (+1.52%)
Latest anomalies
Negative 1 detected in the last 120 days
- High: 1
- Medium: 1
- Low: 0
Realized volatility: a breakout above its trailing average
Capital expenditure to revenue: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA40390B1094
- CUSIP
- 40390B109
Company
- Employees
- 92
- Headquarters
- Etobicoke, Canada
Market
- Shares outstanding
- 30.9M
- Market cap
- CA$125.58M
Key dates
- Next earnings
- Nov 12, 2026
Highlights
- Market cap
- CA$125.58M
- EPS LTM
- -$0.48calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- $56.42M-4.2%down year on year
- Net income
- -$15.04M+37.55%up year on year
- Gross margin
- 82.59%-3.52%down year on year
- Free cash flow
- $11.73M-4.94%down year on year
Latest news
News is not sourced for this exchange.
Business summary
HLS Therapeutics Inc is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker HLS. Its market capitalisation is CA$125.58M, from 30.9M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$3.56 and CA$5.77, and the last close of CA$4.00 sits 20% of the way up that range. The company is headquartered in Etobicoke, Canada, and employs about 92 people.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company's lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.